Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
d. Any other systemic anti-cancer therapy
e. Palliative care only
Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
a. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
b. Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
c. Nivolumab monotherapy
d. Nivolumab and Ipilimumab
e. Any other systemic anti-cancer therapy
f. Palliative care only
Q3. Does your trust participate in any active clinical trials for the treatment of gastric cancer or cancer of the gastro-oesophageal junction? If so, can you please provide the name of each trial and the number of patients taking part.
Q4. Does your trust participate in any active clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part.
